Start here if you're new
what it is
Talkspace sells online therapy and psychiatry to insurers, employers, and people paying for care themselves.
how it gets paid
Last year Talkspace made $229M in revenue. health plans and EAP was the main engine at $126M, or 55% of sales.
why it's growing
Revenue grew 22.0% last year. Revenue rose 179% vs. prior year in the latest quarter.
what just happened
Talkspace printed $166M in quarterly revenue with $0.02 EPS, showing the business finally has some operating leverage.
At a glance
B balance sheet — gets the job done, barely
0.3x trailing p/e — the market's not buying it — or you found a deal
1.0% return on capital — nothing to write home about
$0.01 fy2024 eps est
$2B fy2026 rev est
xvary composite: 47/100 — below average
What they do
Talkspace sells online therapy and psychiatry to insurers, employers, and people paying for care themselves.
Mental health care is messy, slow, and full of paperwork. Talkspace makes it easier to get matched with care through insurers, employers, or your phone, and that convenience matters when 1.2 million members have used the platform. Its edge is distribution, not magic: health plans like Aetna, Cigna, and Optum can send patients into one virtual system instead of building their own.
How they make money
$229M
annual revenue · their business grew +22.0% last year
health plans and EAP
$126M
+29.0%
direct-to-enterprise
$46M
+22.0%
therapy subscriptions
$34M
+22.0%
psychiatry and medication management
$18M
+22.0%
other services
$5M
+22.0%
The products that matter
insurance and employer contracts
payor segment
~$137M · roughly 60% of revenue
this business grew 40% last year. it is the engine behind management's $275M–$290M revenue target for 2026.
growth engine
direct therapy subscriptions
consumer segment
~$92M · roughly 40% of revenue
it still reaches 1.2 million members, but flat growth means the market is paying more attention to payor execution than app demand.
scale, not speed
therapy delivery platform
care delivery
1.6M sessions in 2025
1.6M annual therapy sessions prove the platform is real. the question is not whether people use it. the question is who controls the economics after the deal closes.
proof of use
Key numbers
$229M
annual revenue
This is the real sales base today, so every growth story should be measured against it, not against fantasy numbers.
1.4%
operating margin
Jargon → operating margin → leftover profit from core operations → so what: the company is profitable, but barely.
$0.08
trailing EPS
Jargon → EPS → profit per share → so what: the stock price is leaning on very small earnings.
$5.25
buyout price
That is the signed acquisition price from UHS, which turns the stock into a spread trade more than a long-term compounding story.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for TALK right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Talkspace printed $166M in quarterly revenue with $0.02 EPS, showing the business finally has some operating leverage.
Revenue rose 179% vs. prior year in the latest quarter, while gross margin was 14.0%. Plain English: sales jumped fast, but profitability is still thin.
$166M
revenue
$0.02
eps
14.0%
gross margin
the number that mattered
The number that mattered was $166M in quarterly revenue because it dwarfs the prior year by 179% and shows scale arriving faster than profit.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is the universal health services acquisition failing or slipping far enough to make the spread stop looking attractive.
med
deal break
the stock is anchored to a $5.25 cash offer. if regulators, financing, or closing conditions break the transaction, TALK goes back to trading on standalone fundamentals.
the gap from $3.77 to $5.25 is about $1.48 per share. that is the premium at risk.
med
closing delay
management expects the deal to close in q3 2026. if that slips, the annualized return from the spread drops and arbitrage holders get less patient.
same $1.48 spread, longer wait. that is how a good headline turns into mediocre economics.
med
operating wobble before close
2026 guidance calls for $275M–$290M of revenue after $228.9M in 2025. if payor growth cools or margins keep slipping from 44.4% to 42.7%, the business loses negotiating strength.
there is no public evidence of a repricing risk today, but weaker prints would give the market one more reason to doubt the path to closing.
the spread is the upside. the failed-deal scenario is the downside. that makes this a risk-arb setup wearing a healthcare ticker.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
q3 2026 deal close target
the signed cash offer is $5.25 per share. every update on timing changes the value of the spread.
metric
payor growth holding near 40%
this is the segment carrying the business. if it cools sharply, the remaining standalone story gets thinner fast.
trend
consumer stays flat while payor does the lifting
60% of revenue is now tied to the faster channel. that mix shift is good for growth, but it also makes the company more dependent on enterprise distribution.
risk
gross margin pressure
q4 gross margin fell to 42.7% from 44.4% from a year ago. one quarter is noise. a pattern is not.
Analyst rankings
risk profile
average
risk rank 3 — typical risk profile — neither especially safe nor risky.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity
institutional ownership data for TALK is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive